display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positivebreast cancer - triple negative
es-BC - HER2 positive - (neo)adjuvant (NA)mBC - Triple negative (TNBC) - 1st Line (L1)es-BC - TNBC - NA - all population
paclitaxel
nab-paclitaxel TORCHLIGHT TORCHLIGHT
paclitaxel followed by doxorubicin plus cyclophosphamide IMpassion-050 IMpassion-050 IMpassion-050 ALEXANDRA/IMpassion-030

Study type: